Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX) reported disappointing results from a Phase II(b) clinical trial of its cocaine addiction treatment CPP-109 sending the stock price plummeting 95 cents to close at $0.50.
Disappointing Results For Catalyst Pharmaceutical
November 08, 2012 at 19:12 PM EST
